66 studies found for:    vaccine adverse reactions | Open Studies
Show Display Options
Rank Status Study
21 Unknown  Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients
Condition: Influenza
Intervention: Drug: AdimFlu-S
22 Recruiting Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus
Conditions: Hepatitis B Infection;   Chronic Infection;   Viremia
Intervention: Drug: TDF treatment
23 Unknown  Modulation of Immune Response by Oral Zinc Supplementation in Chemotherapy for Colon Cancer
Conditions: Adjuvant Chemotherapy;   Colon Cancer;   Immunity
Interventions: Dietary Supplement: zinc;   Other: Placebo
24 Recruiting A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
Condition: Meningococcal Vaccine
Interventions: Biological: rLP2086;   Biological: Havrix (HAV);   Biological: Saline
25 Recruiting A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
Condition: Healthy
Interventions: Biological: rLP2086;   Other: Placebo
26 Recruiting A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects
Condition: Influenza
Intervention: Biological: AdimFlu-V
27 Recruiting A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old
Condition: Influenza
Intervention: Biological: AdimFlu-V
28 Recruiting Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: carcinoembryonic antigen-expressing measles virus;   Genetic: fluorescence in situ hybridization;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: needle biopsy;   Procedure: neoadjuvant therapy
29 Recruiting Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan
Condition: Clostridium Difficile Infection
Interventions: Biological: Clostridium difficile Toxoid Vaccine;   Biological: 0.9% normal saline
30 Unknown  A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso
Condition: Malaria
Interventions: Biological: MSP 3 Long Synthetic Peptide;   Biological: Hepatitis B vaccine;   Biological: Hepatitis B control vaccince
31 Not yet recruiting Safety Study of Live Shigella Vaccine in Bangladeshi Adults and Children
Condition: Diarrhea
Intervention: Biological: WRSS1
32 Not yet recruiting A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines
Condition: Cholera
Intervention: Biological: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
33 Recruiting A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
Condition: Influenza (Seasonal)
Interventions: Biological: Novartis MF59-adjuvanted influenza subunit vaccine;   Biological: Sandoz Korea MF59-adjuvanted influenza subunit vaccine
34 Recruiting Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
Condition: Clostridium Difficile Infection
Interventions: Biological: C. difficile Toxoid Vaccine;   Biological: Placebo: 0.9% normal saline
35 Recruiting Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults
Condition: Safety of Candidate Malaria Vaccine
Interventions: Biological: Group A1 : 50µg AMA1-DiCo + Alhydrogel;   Biological: Group A2 : 50 µg AMA1-DiCo+ GLA-SE;   Biological: Group B2 : Placebo
36 Unknown  Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545])
Condition: Malaria
Interventions: Biological: Malaria vaccine AMA1 (PfAMA-1-FVO[25-545];   Biological: AMA1
37 Recruiting Regulatory Post-Marketing Surveillance Study for TETRAXIM™
Conditions: Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis
Intervention: Biological: TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio
38 Recruiting Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 4 Years Old
Condition: Influenza
Intervention: Biological: TIV
39 Recruiting Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants
Condition: Evaluation of a Rotavirus Vaccine
Interventions: Biological: P2VP8 Subunit Vaccine 10mcg;   Biological: P2VP8 Subunit Vaccine 30 mcg;   Biological: P2VP8 Subunit Vaccine 60mcg;   Biological: Placebo;   Biological: Cohort B2 P2VP8 D1;   Biological: Cohort B2 P2VP8 D2
40 Recruiting Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
Condition: B-cell Chronic Lymphocytic Leukemia
Interventions: Biological: B-CLL Vaccine;   Drug: Lenalidomide

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years